SK’s Narcolepsy Therapy Ready For U.S. Phase III Trial
This article was originally published in PharmAsia News
Executive Summary
South Korean conglomerate SK Group is making some progress in new drug development, with its affiliate SK Biopharmaceuticals poised to begin Phase III clinical trials in the U.S. with a treatment for narcolepsy.